Filing Details
- Accession Number:
- 0001474506-21-000159
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-04 20:09:49
- Reporting Period:
- 2021-11-02
- Accepted Time:
- 2021-11-04 20:09:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1267602 | Alimera Sciences Inc | ALIM | Pharmaceutical Preparations (2834) | 200028718 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1344927 | R James Largent | 4040 Macarthur Boulevard Suite 240 Newport Beach CA 92660 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-03 | 10,000 | $4.31 | 13,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-11-02 | 6,000 | $0.00 | 6,000 | $4.05 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
6,000 | 2031-11-01 | No | 4 | A | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.11 to $4.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Vests in full on June 15, 2022, provided the Reporting Person provides continuous service to the Issuer through such date.